Cargando…

Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study

BACKGROUND: Grade 3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) origin with Ki-67 indices <55% do not respond well to platinum-based chemotherapy. The combination of capecitabine and temozolomide (CAPTEM) has shown favorable responses in grade 1-2 NENs, but has rarely been stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, H., Shin, J., Jeong, J.H., Kim, K.-p., Hong, S.-M., Kim, Y.-i., Ryu, J.-S., Ryoo, B.-Y., Yoo, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099746/
https://www.ncbi.nlm.nih.gov/pubmed/33901869
http://dx.doi.org/10.1016/j.esmoop.2021.100119
_version_ 1783688636973187072
author Jeong, H.
Shin, J.
Jeong, J.H.
Kim, K.-p.
Hong, S.-M.
Kim, Y.-i.
Ryu, J.-S.
Ryoo, B.-Y.
Yoo, C.
author_facet Jeong, H.
Shin, J.
Jeong, J.H.
Kim, K.-p.
Hong, S.-M.
Kim, Y.-i.
Ryu, J.-S.
Ryoo, B.-Y.
Yoo, C.
author_sort Jeong, H.
collection PubMed
description BACKGROUND: Grade 3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) origin with Ki-67 indices <55% do not respond well to platinum-based chemotherapy. The combination of capecitabine and temozolomide (CAPTEM) has shown favorable responses in grade 1-2 NENs, but has rarely been studied in patients with grade 3 NENs. PATIENTS AND METHODS: This open-label, single-arm phase II trial included patients with unresectable or metastatic grade 3 NENs of GEP origin with Ki-67 indices <55% enrolled between June 2017 and July 2020. Patients received oral capecitabine 750 mg/m(2) twice daily on days 1 to 14 and oral temozolomide 200 mg/m(2) once daily on days 10 to 14 every 4 weeks. Histologic findings were centrally reviewed after the completion of enrollment. The primary endpoint was overall response rate, and the secondary endpoints were progression-free survival (PFS), overall survival (OS), and adverse events. RESULTS: Of the 30 patients included in the full analysis set, 1 (3.3%) achieved complete response, 8 (26.7%) had partial responses, and 14 (46.7%) had stable disease, making the overall response rate 30.0%. At a median follow-up of 19.2 months, the median PFS was 5.9 months and the median OS was not reached. Patients with well-differentiated NENs showed significantly better median PFS (9.3 months versus 3.5 months, P = 0.005) and median OS (not reached versus 6.2 months, P = 0.004) than patients with poorly differentiated tumors. Expression of O(6)-methyl-guanine methyltransferase protein did not correlate with clinical outcomes. The most common grade 3-4 adverse events were thrombocytopenia (10%), anemia (6.7%), and nausea (6.7%). CONCLUSIONS: CAPTEM was effective and well tolerated in patients with grade 3 GEP-NENs with Ki-67 indices <55%, with superior efficacy outcomes compared with the historical controls receiving platinum-based chemotherapy.
format Online
Article
Text
id pubmed-8099746
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80997462021-05-13 Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study Jeong, H. Shin, J. Jeong, J.H. Kim, K.-p. Hong, S.-M. Kim, Y.-i. Ryu, J.-S. Ryoo, B.-Y. Yoo, C. ESMO Open Original Article BACKGROUND: Grade 3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) origin with Ki-67 indices <55% do not respond well to platinum-based chemotherapy. The combination of capecitabine and temozolomide (CAPTEM) has shown favorable responses in grade 1-2 NENs, but has rarely been studied in patients with grade 3 NENs. PATIENTS AND METHODS: This open-label, single-arm phase II trial included patients with unresectable or metastatic grade 3 NENs of GEP origin with Ki-67 indices <55% enrolled between June 2017 and July 2020. Patients received oral capecitabine 750 mg/m(2) twice daily on days 1 to 14 and oral temozolomide 200 mg/m(2) once daily on days 10 to 14 every 4 weeks. Histologic findings were centrally reviewed after the completion of enrollment. The primary endpoint was overall response rate, and the secondary endpoints were progression-free survival (PFS), overall survival (OS), and adverse events. RESULTS: Of the 30 patients included in the full analysis set, 1 (3.3%) achieved complete response, 8 (26.7%) had partial responses, and 14 (46.7%) had stable disease, making the overall response rate 30.0%. At a median follow-up of 19.2 months, the median PFS was 5.9 months and the median OS was not reached. Patients with well-differentiated NENs showed significantly better median PFS (9.3 months versus 3.5 months, P = 0.005) and median OS (not reached versus 6.2 months, P = 0.004) than patients with poorly differentiated tumors. Expression of O(6)-methyl-guanine methyltransferase protein did not correlate with clinical outcomes. The most common grade 3-4 adverse events were thrombocytopenia (10%), anemia (6.7%), and nausea (6.7%). CONCLUSIONS: CAPTEM was effective and well tolerated in patients with grade 3 GEP-NENs with Ki-67 indices <55%, with superior efficacy outcomes compared with the historical controls receiving platinum-based chemotherapy. Elsevier 2021-04-23 /pmc/articles/PMC8099746/ /pubmed/33901869 http://dx.doi.org/10.1016/j.esmoop.2021.100119 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Jeong, H.
Shin, J.
Jeong, J.H.
Kim, K.-p.
Hong, S.-M.
Kim, Y.-i.
Ryu, J.-S.
Ryoo, B.-Y.
Yoo, C.
Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
title Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
title_full Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
title_fullStr Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
title_full_unstemmed Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
title_short Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
title_sort capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with ki-67 index <55%: single-arm phase ii study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099746/
https://www.ncbi.nlm.nih.gov/pubmed/33901869
http://dx.doi.org/10.1016/j.esmoop.2021.100119
work_keys_str_mv AT jeongh capecitabineplustemozolomideinpatientswithgrade3unresectableormetastaticgastroenteropancreaticneuroendocrineneoplasmswithki67index55singlearmphaseiistudy
AT shinj capecitabineplustemozolomideinpatientswithgrade3unresectableormetastaticgastroenteropancreaticneuroendocrineneoplasmswithki67index55singlearmphaseiistudy
AT jeongjh capecitabineplustemozolomideinpatientswithgrade3unresectableormetastaticgastroenteropancreaticneuroendocrineneoplasmswithki67index55singlearmphaseiistudy
AT kimkp capecitabineplustemozolomideinpatientswithgrade3unresectableormetastaticgastroenteropancreaticneuroendocrineneoplasmswithki67index55singlearmphaseiistudy
AT hongsm capecitabineplustemozolomideinpatientswithgrade3unresectableormetastaticgastroenteropancreaticneuroendocrineneoplasmswithki67index55singlearmphaseiistudy
AT kimyi capecitabineplustemozolomideinpatientswithgrade3unresectableormetastaticgastroenteropancreaticneuroendocrineneoplasmswithki67index55singlearmphaseiistudy
AT ryujs capecitabineplustemozolomideinpatientswithgrade3unresectableormetastaticgastroenteropancreaticneuroendocrineneoplasmswithki67index55singlearmphaseiistudy
AT ryooby capecitabineplustemozolomideinpatientswithgrade3unresectableormetastaticgastroenteropancreaticneuroendocrineneoplasmswithki67index55singlearmphaseiistudy
AT yooc capecitabineplustemozolomideinpatientswithgrade3unresectableormetastaticgastroenteropancreaticneuroendocrineneoplasmswithki67index55singlearmphaseiistudy